Evaluating the utility of proteomics for the identification of circulating pharmacodynamic biomarkers of IFNβ-1 biologics. Evaluating the utility of proteomics for the identification of circulating pharmacodynamic biomarkers of IFNβ-1 biologics

In this study, we evaluated the utility of proteomics to identify plasma proteins in healthy participants from a phase I clinical trial with IFNβ-1a and pegIFNβ-1a biologics to identify potential pharmacodynamic (PD) biomarkers. Using a linear mixed-effects model with repeated measurement for product-time interaction, we found that 248 and 528 analytes detected by the SOMAscan® assay were differentially expressed (p-value 7000 proteins from 12 subjects treated with IFNβ-1a, 12 with pegIFNβ-1a and 12 with placebo. The 12 subjects on IFNβ-1a were tested at 10 timepoints over 6 days, and the rest were tested at 12 time points over 13 days. Replicates for 4 random samples were included on the array. Two covid covalacent plasma samples were also included on the array. Submitter states: Raw data is normalized using specific plasma standards by the manufacturer. The raw data can not be used as is.